ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE

ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE

The incidence of chronic kidney disease (CKD) in Type 2 Diabetes Mellitus patients accounts for 34,6–40% of cases. The importance of glycemic control for the prevention of kidney damage and progression of nephropathy in T2DM patients is proven in numerous studies. The presence of CKD significantly...

Full description

Bibliographic Details
Main Author:	I. A. Bonda
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2017-07-01
Series:	Медицинский совет
Subjects:	diabetes mellitus chronic kidney disease a dpp-4 inhibitor glp-1 sitagliptin
Online Access:	https://www.med-sovet.pro/jour/article/view/1936

Similar Items

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study
by: Hiroshi Sakura, et al.
Published: (2016-12-01)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
by: Li Zhang, et al.
Published: (2023-09-01)

DPP‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia
by: Dwight D. Harris, et al.
Published: (2024-03-01)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

Treatment of diabetes mellitus in patients with chronic kidney disease - a review of the latest research.
by: Natalia Wierzbowska, et al.
Published: (2022-03-01)

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01)

Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus
by: Sachiko Hattori
Published: (2021-10-01)

Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
by: Elena-Daniela Grigorescu, et al.
Published: (2023-08-01)

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
by: Alexander Sergeevich Ametov, et al.
Published: (2010-09-01)

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)
by: Naoto Katakami, et al.
Published: (2018-02-01)

Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism
by: Güle ÇINAR, et al.
Published: (2022-06-01)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
by: Soon Ae Kim, et al.
Published: (2011-04-01)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
by: Masahiro Fukuda, et al.
Published: (2019-03-01)

Safety and Efficacy of Sitagliptin compared with Glimepiride in Patients with Type 2 Diabetes Mellitus inadequately controlled with Metfromin Monotherapy
by: Amjad Abrar, et al.
Published: (2013-07-01)

Oat globulin peptides regulate antidiabetic drug targets and glucose transporters in Caco-2 cells
by: Feng Wang, et al.
Published: (2018-03-01)

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model
by: Amy L. Wilson, et al.
Published: (2021-01-01)

Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
by: Le TD, et al.
Published: (2020-06-01)

The Effects of the New Therapeutic Treatments for Diabetes Mellitus on the Male Reproductive Axis
by: Carla Pelusi, et al.
Published: (2022-04-01)

An Effective Delivery System of Sitagliptin Using Optimized Mucoadhesive Nanoparticles
by: Afzal Haq Asif, et al.
Published: (2018-05-01)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012-03-01)

Efficacy and safety of metformin and sitagliptin‐based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study
by: Xiangyang Liu, et al.
Published: (2020-11-01)

Type 2 diabetes mellitus in elderly patients treated with endocrinologists in clinical practice
by: Elena V. Biryukova
Published: (2019-12-01)

Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
by: Won Jun Kim, et al.
Published: (2011-06-01)

DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
by: Seung Jung Kim, et al.
Published: (2019-03-01)

Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats
by: Yu-Sheng Liu, et al.
Published: (2015-03-01)

Role of incretin based therapies in the treatment of diabetic kidney disease
by: Paola Fioretto, et al.
Published: (2018-11-01)

Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
by: Sharma A, et al.
Published: (2022-06-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
by: Honghong Zou, et al.
Published: (2017-05-01)

Antidiabetic Effects of Aloe Vera Whole Leaf Extract and Sitagliptin in Streptozotocin-induced Diabetic Rats
by: Sobia Javaid, et al.
Published: (2020-12-01)

Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
by: Sanbao Chai, et al.
Published: (2022-07-01)

Effects of metformin+sitagliptin versus metformin + glibenclamide combinations on lipid profile, body mass index and kidney function in Iraqi patients with type 2 diabetes mellitus.
by: Hassan Mohammed Abbas Al-Temimi, et al.
Published: (2013-06-01)

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells
by: Tomohiro Komatsu, et al.
Published: (2023-01-01)

Oxidative stress markers in liver in streptozocin-induced diabetic rats: effects of metformin and sitagliptin
by: Şamil Öztürk, et al.
Published: (2020-12-01)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
by: Shin S, et al.
Published: (2016-03-01)

ASSESSMENT OF SITAGLIPTIN INFLUENCE ON ARTERIAL WALL STIFFNESS, RENAL FUNCTION AND RENAL CIRCULATION IN CARDIOVSCULAR PATIENTS WITH DECOMPENSATED TYPE 2 DIABETES
by: E. V. Oskola, et al.
Published: (2015-03-01)

Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
by: Chia-Jen Tsai, et al.
Published: (2022-11-01)